腎移植後サイトメガロウイルス感染症の診療ガイドライン　2011

出版社： 日本医学館
著者：
発行日： 2011-10-01
分野： 臨床医学：外科  >  泌尿器科学
ISBN： 9784890447374
電子書籍版： 2011-10-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

1,650 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

825 円(税込)

購入する

商品紹介

日本の現状を反映した、腎移植後サイトメガロウイルス感染症の診療ガイドライン。感染および感染症の定義から診断に至る検査法、予防を含めた治療法までを記載。エビデンスレベル、推奨グレードを付記する。

目次

  • 腎移植後サイトメガロウイルス感染症の診療ガイドライン　2011

    ―目次―

    GUIIDE 1　サイトメガロウイルス（CMV）感染症とは
    GUIIDE 2　腎移植後CMV感染の診断法I
    GUIIDE 3　腎移植後CMV感染の診断法II
    GUIIDE 4　腎移植後CMV感染の治療薬
    GUIIDE 5　腎移植CMV D+/R-症例におけるCMV感染症対策

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

GUIDE 2 腎移植後CMV感染の診断法I

P.8 掲載の参考文献
1) 大黒 徹, 武本眞清, 白木公康: サイトメガロウイルス感染症の基礎研究. 今日の移植 23:180-189,2010. [エビデンスレベルIII]
 
2) Rayes N, Seehofer D, Lullius SG et al.: Monitoring of human cytomegalovirus, HHv-6 and HHV-7 infection in kidney transplant recipients by molecular methods to predict HCMV disease after transplantation: A prospective study. Ann Transplant 10:23, 2005. [エビデンスレベルIII]
 
3) Schroeder R, Michelon T, Fagundes I et al.:Antigenemia for cytomegalovirus in renal transplantation: Choosing a cut off for the diagnosis criteria in cytomegalovirus disease. Transplant Proc 37:2781-2783, 2005. [エビデンスレベルIII]
 
4) The TH, Van der Gij W, Van den Berg AP et al.: Cytomegalovirus antigenemia. Rev inf Dis 12(Suppl 7): s737-744, 1990.
 
5) Masuho Y et al.: Human monoclonal antidodies neutralizing human cytomegalovirus. J Gen Virol 68:1457-1461, 1987.
 
6) 渡井至彦: 腎移植における長期生着を目指して-ウイルス感染. 今日の移植 23:1, 90-95, 2010. [エビデンスレベルIVb]
 
7) Piiparinen H, Hockerstedt K, Gronhagen-Riska et al.: Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV Monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients. J Clin Virol 30:258, 2004. [エビデンスレベルIII]
 
8) Gerna G. Baldanti F, Torsellini M et al.: Evaluation of cytomegalovirus DNAaemia versus pp65-antigenemia cut off for guiding preemptive therapy in transplant recipients; A randomizes study. Antivir Ther 12:63, 2007. [エビデンスレベルIVa]
 
9) Small LN, Lau J, Snydman DR: Preventing Post-organ transplantation cytomegalovirus disease with ganciclovir: A Mata-Analysis Comparing Prophylactic and preemptive Therapies. Clinical Infectious Disease 43:869-880,2006. [エビデンスレベルI]
 
10) Sun HY, Wagener MM, Singh N: Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A Systemic Review AJT 8:2111-2118, 2008. [エビデンスレベル1]
 
11) Preiksaitis JK, Brennan DC, Fishman J, Allen U: Canadian Society of Transplantation Consensus Workshop on cytomegalovirus management in solid organ tranaplantation final report. AJT 5:218-227, 2005.
 

GUIDE 3 腎移植後CMV感染の診断法II

P.14 掲載の参考文献
1) Kotton CN, Kumar D, Caliendo AM, Asberg A, Sunwen C, Snydman DR, Allen U, Humar A: On behalf of the Transplantation Society Infectional CMV Consensus Group. International Consensus Guidelines in the Management of Cytomegalovirus in Solid Organ Transplantation. Transplantation 89:779-795, 2010.
 
2) Kotton CN: Management of cytomegalovirus infection in solid organ transplantation. Nat Rev Nephrol 6:711-721, 2010.
PubMed
3) Humar A, Snydman D: AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9(Suppl 4): S78-86, 2009.
 
4) Humar A, Michaels M: On behalf of the AST ID working group on Infectious Disease Monitoring. American Society of Transplantation Recommendations for Screening, Monitoring and Reporting of Infectious Complications in Immunosuppression Trials in Recipients of Organ Transplantation. Am J Transplant 6:262-274, 2006.
 
5) Demirkazik FB, Akin A, Uzun O, Akpinar MG, Ariyurek MO: CT findings on immunocompromised patients with pulmonary infections. Diagn Interv Radiol 14:75-82, 2008.
PubMed
6) Gasparetto EL, Ono SE, Escuissato D, Marchiori E, Roldan L, Marques HL, Fraree Silva RL: Cytomegarovirus pneumonia after bone marrow transplantation: high resolution CT findings. Br J Radiol 77:724-727, 2004.
 
7) Gulati M, Kaur R. Jha V, Venkataramu NK, Gupta D, Suri S: High-resolution CT in renal transplant patients with suspected pulmonary infections. Acta Radiol 41:237-241, 2000.
PubMed
8) Eun-Young K, Patz EF, Muller NL: Cytomegalovirus pneumonia in transplant patients: CT Findings. J Comp Assist Tomograph 20:295-299, 1996.
 
9) Peter A, Telkes G, Varga M, Sarvary E, Kovalszky I: Endoscopic diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 18(5):580-584. 2004 Oct.
PubMed
10) Ponticelli C, Passerini P: Gastrointestinal complications in renal transplant recipients. Transpl Int 18(6):643-650, 2005 Jun.
PubMed
11) Lempinen M, Halme L, Sarkio S, Arola J, Honkanen E, Turunen U, Salmela K, Lautenschlager I: CMV findings in the gastrointestinal tract in kidney transplantation patients, patients with end-stage kidney disease and immunocompetent patients Nephrol Dial Transplant 24:3533-3539, 2009.
PubMed
12) Sanghera NK, Newman TL: Cytomegaloviral retinitis from chronic immunosuppression following solid organ transplant surgery. Clin Exp Optom 93:4:261-263. 2010.
PubMed
13) Chung H, Kim KH, Kim JG, Lee SY, Yoon YH: Retinal Complications in Patients With Solid Organ or Bone Marrow Transplantation. Transplantation 83:694-699s, 2007.
PubMed
14) Hantz S, Garnier-Geoffroy F, Mazeron MC et al.: French CMV Resistance Survey Study Group. Drug-resistant cytomegalovirus in transplant recipients: a French cohort study. J Antimicrob Chemother 65:2628-2640, 2010.
 
15) Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y, Kanda Y, Miyawaki T, Shiraki K: Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J pharmacol Exp Ther 333(3):816-821, 2010.
PubMed

GUIDE 4 腎移植後CMV感染症の治療薬

P.21 掲載の参考文献
1) Asberg A, Humar A, Rollag H et al.: Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7:2106, 2007.
PubMed
2) Kotton CN, Kumar D, Caliendo AM et al.:International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89(7):779, 2010.
PubMed
3) Humar A, Snydman D, the AST infectious disease community of practice: Am J Transplant 9:S78,2009.
 
4) 造血細胞移植ガイドライン-サイトメガロウイルス感染症. 日本造血細胞移植学会ガイドライン委員会 ｢サイトメガロウイルス感染症｣ 作業部会, 日本造血細胞移植学会ガイドライン委員会, 1999.
 
5) Humar A, Lebranchu Y, Vincenti F, et al.: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10:1, 2010. [エヒテンスレベルII]
 
6) Sun HY, Wagener MM, Singh N: Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: A systematic review. Am J Transplant 8:2111, 2008. [エビデンスレベルI]
 
7) Khoury JA, Storch GA, Bohl DL et al: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6:2134, 2006. [エビデンスレベルII]
 
8) Afrani L, Truffaut L, Kreis H et al.: Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: A retrospective study. Am J Transplant 9:1816, 2009. [エビデンスレベルIVa]
 
9) Asberg A, Jardine AG, Bignamini AA et al.: Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ Transplant recipients. AJT 10:1.8.2010. [エビデンスレベルII]
 
10) 渡井至彦: 腎移植における長期生着を日指して-ウイルス感染. 今日の移植 23(1): 90-95, 2010. [エビデンスレベルIVb]
 
11) Danziger-Isakov L, Baillie GM: Hematologic complications of anti-CMV therapy in solid organ transplant recipient. Clin Transplant 23(3):295-304, 2008. [エビデンスレベルI]
 
12) Snydman DR, Werner BG, Heinze-Lacey B et al.: Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipient. N Engl J Med 317:1049-1054, 1987. [エビデンスレベルII]
 
13) Snydman DR: Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl Infect Dis 3(Suppl 2):6-13, 2001. [エビデンスレベルIII]
 
14) Snydman DR. Werner BG, Tilney NL et al.: Final analysis of primery cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: Comparison of the randomized and open-label Trials. Transplant Proc 23:1357-1360, 1991. [エビデンスレベルIVa]
 

GUIDE 5 腎移植CMV D+/R-症例におけるCMV感染症対策

P.25 掲載の参考文献
1) Humar A, Snydman D: Cytomegalovirus in solid organ transplant recipients. Am J Transplant 9(Suppl 4):S78, 2009.
 
2) Khoury JA, Storch GA, Bohl DL et al.: Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6(9):2134, 2006. [エビデンスレベルII]
 
3) Reischig T, Jindra P, Hes O, Svecova M, Klaboch J, Treska V: Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 8(1):69, 2008. [エビデンスレベルII]
 
4) Paya C, Humar A, Dominguez E et al.: Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 4(4):611, 2004. [エビデンスレベルII]
 
5) Humar A, Lebranchu Y, Vincenti F et al.: The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 10(5):1228-1237, 2010. [エビデンスレベルII]
 
6) Humar A, Paya C, Pescovitz MD et al.: Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R-solid organ transplant recipients. Am J Transplant 4(4):644, 2004.
 
7) Sun HY, Wagener MM, Singh N. Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review. Am J Transplant 8(10):2111, 2008. [エビデンスレベルI]
 
8) Small LN, Lau J, Snydman DR: Preventing Post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies. Clin Infect Dis 43(7):869, 2006. [エビデンスレベルI]
 
9) Preiksaitis JK, Brennan DC, Fishman J, Allen U: Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5(2):218, 2005.
PubMed
10) Schroeder R, Michelon T, Fagundes I et al.: Antigenemia for cytomegalovirus in renal transplantation: choosing a cutoff for the diagnosis criteria in cytonlegalovirus disease. Transplant Proc 37(6):2781, 2005. [エビデンスレベルIII]
 
11) The TH, van der Bij W, van den Berg AP et al.: Cytomegalovirus antigenemia. Rev Infect Dis 12(Suppl 7):S734, 1990.
 
12) Masuho Y, Matsumoto Y, Sugano T, Fujinaga S, Minamishima Y: Human monoclonal antibodies neutralizing human cytomegalovirus. J Gen Virol 68(Pt 5):1457, 1987.
 

書評

最近チェックした商品履歴

Loading...